Drug intelligence / Profile preview

[123I]-IBVM

Development stage: Phase 2
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration: Intravenous

Overview

[123I]-IBVM is a radiopharmaceutical compound used primarily as a highly selective radioligand for in vivo visualization of the vesicular acetylcholine transporter (VAChT) in the brain. It is utilized with single photon emission computed tomography (SPECT) imaging to study cholinergic neuron integrity, particularly in neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies. By binding selectively to VAChT, [123I]-IBVM enables noninvasive quantification of cholinergic terminal density and function, providing valuable insights into disorders characterized by cholinergic deficits[1][6].

Other names: [123I]-iodobenzovesamicoliodobenzovesamicol

Targets

SLC18A3 (Vesicular acetylcholine transporter)

Beyond the preview

Go deeper on [123I]-IBVM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [123I]-IBVM.